Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis

Podobne knjige/članki

• Steroid use in PROWESS severe sepsis patients treated with drotrecogin alfa (activated)
  od: Levy, Howard, et al.
  Izdano: (2005)
• Clinical trials in severe sepsis with drotrecogin alfa (activated)
  od: Laterre, Pierre-François
  Izdano: (2007)
• The efficacy of Drotrecogin alfa (activated) during a global, single-arm, open-label trial in adult patients with severe sepsis (ENHANCE): comparisons with PROWESS
  od: Vincent, J, et al.
  Izdano: (2004)
• Clinical review: Drotrecogin alfa (activated) as adjunctive therapy for severe sepsis – practical aspects at the bedside and patient identification
  od: Laterre, Pierre-François, et al.
  Izdano: (2003)
• Drotrecogin alfa (activated) in the subgroup of patients with multiple organ dysfunction (MOD) during a global, single-arm, open-label trial in adult patients with severe sepsis (ENHANCE): comparisons with PROWESS
  od: Vincent, J, et al.
  Izdano: (2004)